Tag: ReCode Therapeutics

ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis

ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis

– The Cystic Fibrosis Foundation has agreed to invest up to $15 million in new funding to support the company’s gene correction development program with Intellia Therapeutics for the treatment of cystic fibrosis– November 18,…

Read More Read More

Recode Therapeutics has filed a notice of an exempt offering of securities to raise $220,801,112.00 in Equity and Debt Financing.

Recode Therapeutics has filed a notice of an exempt offering of securities to raise $220,801,112.00 in Equity and Debt Financing.

According to filings with the U.S. Securities and Exchange Commission, Recode Therapeutics is raising $220,801,112.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Shehnaaz Suliman played a key role in…

Read More Read More